Sleeve Lobectomy Compared to Pneumonectomy for the Treatment of N0-N1 Non-Small Cell Lung Cancer

Jiménez, M.F.; Varela, G.; Novoa, N.; Aranda, J.L.

doi:10.1016/S1579-2129(06)60436-9

Archivos de Bronconeumología

ISSN: 0300-2896

Archivos de Bronconeumologia is a scientific journal that preferentially publishes prospective original research articles whose content is based upon results dealing with several aspects of respiratory diseases such as epidemiology, pathophysiology, clinics, surgery, and basic investigation. Other types of articles such as reviews, editorials, a few special articles of interest to the society and the editorial board, scientific letters, letters to the Editor, and clinical images are also published in the Journal. It is a monthly Journal that publishes a total of 12 issues and a few supplements, which contain articles belonging to the different sections.

All the manuscripts received in the Journal are evaluated by the Editors and sent to expert peer-review while handled by the Editor and/or an Associate Editor from the team. The Journal is published monthly in English.

Manuscripts will be submitted electronically using the following web site: https://www.editorialmanager.com/ARBR/, link which is also accessible through the main web page of Archivos de Bronconeumologia.

Access to any published article, is possible through the Journal's web page as well as from PubMed, Science Direct, and other international databases. Furthermore, the Journal is also present in Twitter and Facebook. The Journal expresses the voice of the Spanish Respiratory Society of Pulmonology and Thoracic Surgery (SEPAR) as well as that of other scientific societies such as the Latin American Thoracic Society (ALAT) and the Iberian American Association of Thoracic Surgery (AICT).

Authors are also welcome to submit their articles to the Journal's open access companion title, Open Respiratory Archives.

Archivos de Bronconeumologia has received the new Impact Factor (JCR). The impact factor has risen from 6.333 in 2021 to 8 in the last evaluated year, 2022.
It is needed to be a member of SEPAR or have a subscription to access full texts of articles published last year. Abstracts are available for all visitors.

Indexed in:

Current Contents/Clinical Medicine, JCR SCI-Expanded, Index Medicus/Medline, Excerpta Medica/EMBASE, IBECS, IME, SCOPUS, IBECS

Subscribe:

Impact factor

The Impact Factor measures the average number of citations received in a particular year by papers published in the journal during the two preceding years.

© Clarivate Analytics, Journal Citation Reports 2022

Impact factor 2022

Citescore

CiteScore measures average citations received per document published.

Citescore 2022

2.8

SJR

SRJ is a prestige metric based on the idea that not all citations are the same. SJR uses a similar algorithm as the Google page rank; it provides a quantitative and qualitative measure of the journal's impact.

SJR 2022

0.434

SNIP

SNIP measures contextual citation impact by wighting citations based on the total number of citations in a subject field.

SNIP 2022

0.437

View more metrics

Open Access Option

Journal Information

Previous article | Next article

Vol. 42. Issue 4.

Pages 160-164 (April 2006)

More article options

Pages 160-164 (April 2006)

Original Articles

DOI: 10.1016/S1579-2129(06)60436-9

Full text access

Sleeve Lobectomy Compared to Pneumonectomy for the Treatment of N0-N1 Non-Small Cell Lung Cancer

Visits

4189

Download PDF

M.F. Jiménez

Corresponding author

mfjl@usal.es

Correspondence. Dr. M.F. Jiménez. Sección de Cirugía Torácica. Hospital Universitario. P.o de San Vicente, 58–182. 37007 Salamanca. España

, G. Varela, N. Novoa, J.L. Aranda

Sectión de Cirugía Torácia, Hospital Universitario, Salamanca, Spain

This item has received

4189 Visits

Article information

Abstract

Bibliography

Download PDF

Statistics

Objective

To compare survival, morbidity, and mortality rates for a series of patients who underwent either bronchoplastic sleeve lobectomy or pneumonectomy to treat non-small cell lung cancer (NSCLC).

Patients and method

We reviewed the clinical records for patients who underwent sleeve lobectomy or pneumonectomy for NSCLC from January 1994 through December 2003.

Results

From January 1994 through December 2003, 35 sleeve lobectomies and 220 pneumonectomies were performed at our department on patients with NSCLC. The perioperative mortality rate was 2.8% for the lobectomy group and 9.1% for the pneumonectomy group. The mean survival time for the pneumonectomy group was 45 months (95% confidence interval [CI], 37–53), with a 5-year survival rate of 32% (SE, 5.1%). The mean survival time for the sleeve lobectomy group was 72 months (95% CI, 56–87) (P≤.0041), with a 5-year survival rate of 56% (SE, 9.6%). If we stratify the groups according to node involvement, patients classified as N0-N1 had a mean survival time of 52 months (95% CI, 43–61), with a 5-year survival rate of 39% (SE, 6.2%) for the pneumonectomy group. The mean survival time for patients undergoing sleeve lobectomy was 75 months (95% CI, 59–92) (P≤.018), with a 5-year survival rate of 60% (SE, 10.4%). Survival for patients with N2 disease was similar to that of patients with N0-N1 disease.

Conclusion

For patients with N0-N1 non-small cell lung cancer, sleeve lobectomy offers better survival than pneumonectomy.

Key words:

Sleeve lobectomy

Lung cancer

Sleeve resection

Survival

Pneumonectomy

Objetivo

Comparar la supervivencia, morbilidad y mortalidad de una serie de pacientes operados por cáncer de pulmón no microcítico (CPNM) mediante lobectomía broncoplástica o neumonectomía.

Pacientes y método

Hemos revisado los datos de pacientes a quienes se realizó una lobectomía broncoplástica o una neumonectomía por CPNM entre enero de 1994 y diciembre de 2003.

Resultados

Entre enero de 1994 y diciembre de 2003 se realizaron en nuestra unidad 35 lobectomías con broncoplastia y 220 neumonectomías en pacientes con CPNM. La mortalidad perioperatoria fue del 2,8% en el grupo de las lobectomías y del 9,1% para las neumonectomías. La media de supervivencia de las neumonectomías fue de 45 meses (intervalo de confianza [IC] del 95%, 37–53) y la supervivencia a los 5 años del 32% (error estándar [EE]: 5,1). En el grupo de lobectomías broncoplásticas la media de supervivencia fue de 72 meses (IC del 95%, 56–87) (p ≤ 0,0041) y la supervivencia a los 5 años del 56% (EE: 9,6). Si estratificamos los grupos según la afectación ganglionar, entre los pacientes clasificados como N0-N1 la media de supervivencia fue de 52 meses (IC del 95%, 43–61) y la supervivencia a los 5 años del 39% (EE: 6,2) en las neumonectomías. Los pacientes con lobectomía broncoplástica presentaron una media de supervivencia de 75 meses (IC del 95%, 59–92) (p ≤ 0,018) y la supervivencia a los 5 años del 60% (EE: 10,4). La supervivencia no fue diferente en caso de enfermedad N2.

Conclusión

La lobectomía broncoplástica ofrece mejor supervivencia que la neumonectomía en pacientes con CPNM con afectación N0-N1.

Palabras clave:

Lobectomia broncoplástica

Cáncer de pulmón

Resecciones broncoplásticas

Supervivencia

Neunonectomía

Full text is only aviable in PDF

REFERENCES

[1]

F Tronc, J Grégoire, J Rouleau, J Deslauriers.

Long-term results of sleeve lobectomy for lung cancer.

Eur J Cardiothorac Surg., 17 (2000), pp. 550-556

Medline

[2]

G Massard, R Kessler, B Gasser, X Ducrocq, S Elia, S Gouzou, et al.

Local control of disease and survival following bronchoplastic lobectomy for non-small cell lung cancer.

Eur J Cardiothorac Surg., 16 (1999), pp. 276-282

Medline

[3]

J Deslauries, J Grégoire, LF Jacques, M Piraux, L Guojin, Y Lacasse.

Sleeve lobectomy versus pneumonectomy for lung cancer: a comparative analysis of survival and sites or recurrences.

Ann Thorac Surg., 77 (2004), pp. 1152-1156

http://dx.doi.org/10.1016/j.athoracsur.2003.07.040 | Medline

[4]

H Suen, BF Meyyers, T Guthrie, MS Pohl, S Sundaresan, CL Roper, et al.

Favorable results after sleeve lobectomy or bronchoplasty for bronchial malignancies.

Ann Thorac Surg., 67 (1999), pp. 1557-1562

Medline

[5]

EA Rendina, F Venuta, T Giacomo, I Flaishman, P Fazi, C Ricci, et al.

Safety and efficacy of bronchovascular reconstruction after induction chemotherapy for lung cancer.

J Thorac Cardiovasc Surg., 114 (1997), pp. 830-837

http://dx.doi.org/10.1016/S0022-5223(97)70088-6 | Medline

[6]

MK Ferguson, AG Lehman.

Sleeve lobectomy or pneumonec-tomy: optimal management strategy using decision analysis techniques.

Ann Thorac Surg., 76 (2003), pp. 1782-1788

Medline

[7]

G Varela, MF Jiménez, N Novoa.

Aplicabilidad de un modelo predictivo de muerte por resección de cáncer de pulmón a la toma de decisiones individualizada.

Arch Bronconeumol., 39 (2003), pp. 249-252

Medline

[8]

M Tedder, MP Anstadt, SD Tedder, JE Lowe.

Current morbidity, mortality, and survival after bronchoplastic procedures for malignancy.

Ann Thorac Surg., 54 (1992), pp. 387-391

Medline

[9]

HJ Schünemann, J Dorn, BJB Grant, W Winkelstein, M Trevisan.

Pulmonary function is a long-term predictor of mortality in general population: 29-year follow-up of the Buffalo health study.

Chest, 118 (2000), pp. 656-664

Medline

[10]

E Fadel, B Yildizeli, AR Chapelier, I Dicenta, S Mussot, PG Dartevelle.

Sleeve lobectomy for bronchogenic cancers: factors affecting survival.

Ann Thorac Surg., 74 (2002), pp. 851-859

Medline

[11]

F Chunwei, W Weiji, Z Xinguan, N Qingzen, J Xiangmin, Z Qingzhen.

Evaluations of bronchoplasty and pulmonary artery recons truction for bronchogenic carcinoma.

Eur J Cardiothorac Surg., 23 (2003), pp. 209-213

Medline

[12]

AE Martin-Ucar, N Chaudhuri, JG Edwards, DA Waller.

Can pneumonectomy for non-small cell lung cancer be avoided? An audit of parenchymal sparing lung surgery.

Eur J Cardiothorac Surg., 21 (2002), pp. 601-605

Medline

[13]

P Icard, JF Regnard, L Guibert, P Magdeleinat, B Jauffret, P Levasseur.

Survival and prognostic factors in patients undergoing parenchymal saving bronchoplastic operation for primary lung cancer: a series of 110 consecutive cases.

Eur J Cardiothorac Surg., 15 (1999), pp. 426-432

Medline

[14]

K Kawahara, S Akamine, T Takahashi, A Nakamura, M Muraoka, H Tsuji, et al.

Management of anastomotic complications after sleeve lobectomy for lung cancer.

Ann Thorac Surg., 57 (1994), pp. 1529-1533

Medline

[15]

I Vogt-Moykopf, T Fritz, G Meyer, H Bulzerbruzk, G Daskos.

Bronchoplastic and angioplastic operation in bronchial carcinoma: long-term results of a retrospective analysis from 1973 to 1983.

Int Surg., 71 (1986), pp. 211-220

Medline